| Effect of HIV antibody VRC01 on viral rebound after treatment interruption KJ Bar, MC Sneller, LJ Harrison, JS Justement, ET Overton, ME Petrone, ... New England Journal of Medicine 375 (21), 2037-2050, 2016 | 473 | 2016 |
| Tenofovir to Prevent Perinatal Transmission of Hepatitis B. G Jourdain, N Ngo-Giang-Huong, L Harrison, iTAP Study Group The New England journal of medicine 378 (24), 2350, 2018 | 314* | 2018 |
| Tenofovir versus placebo to prevent perinatal transmission of hepatitis B G Jourdain, N Ngo-Giang-Huong, L Harrison, L Decker, W Khamduang, ... New England Journal of Medicine 378 (10), 911-923, 2018 | 305 | 2018 |
| Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy AM Geretti, L Harrison, H Green, C Sabin, T Hill, E Fearnhill, D Pillay, ... Clinical infectious diseases 48 (9), 1296-1305, 2009 | 198 | 2009 |
| First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected … PENPACT-1 (PENTA 9/PACTG 390) Study Team The Lancet infectious diseases 11 (4), 273-283, 2011 | 145* | 2011 |
| First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected … PENPACT-1 (PENTA 9/PACTG 390) Study Team The Lancet Infectious Diseases 11 (4), 273-283, 2011 | 128 | 2011 |
| First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected … PENPACT-1 (PENTA 9/PACTG 390) Study Team The Lancet infectious diseases 11 (4), 273-283, 2011 | 128 | 2011 |
| Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study AM La Rosa, LJ Harrison, B Taiwo, CL Wallis, L Zheng, P Kim, ... The Lancet HIV 3 (6), e247-e258, 2016 | 81 | 2016 |
| Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a … G Jourdain, N Ngo-Giang-Huong, TR Cressey, L Hua, L Harrison, ... BMC infectious diseases 16, 1-6, 2016 | 43 | 2016 |
| Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age AL Ciaranello, K Doherty, M Penazzato, JC Lindsey, L Harrison, K Kelly, ... Aids 29 (10), 1247-1259, 2015 | 41 | 2015 |
| Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age AL Ciaranello, K Doherty, M Penazzato, JC Lindsey, L Harrison, K Kelly, ... Aids 29 (10), 1247-1259, 2015 | 41 | 2015 |
| The effect of transmitted HIV-1 drug resistance on pre-therapy viral load L Harrison, H Castro, P Cane, D Pillay, C Booth, A Phillips, AM Geretti, ... Aids 24 (12), 1917-1922, 2010 | 41 | 2010 |
| Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis F Martin, H Castro, C Gabriel, A Adonis, A Fedina, L Harrison, L Brodnicki, ... PLoS neglected tropical diseases 6 (6), e1675, 2012 | 40 | 2012 |
| Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation DE Yin, MG Warshaw, WC Miller, H Castro, SA Fiscus, LM Harper, ... Pediatrics 134 (4), e1104-e1116, 2014 | 38 | 2014 |
| Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor TJ Barber, L Harrison, D Asboe, I Williams, S Kirk, R Gilson, L Bansi, ... Journal of antimicrobial chemotherapy 67 (4), 995-1000, 2012 | 36 | 2012 |
| Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3–< 36 months Paediatric European Network for Treatment of AIDS (PENTA) Antiviral therapy 15 (3), 297-305, 2010 | 35 | 2010 |
| Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal tenofovir disoproxil fumarate to prevent mother-to-child … N Salvadori, B Fan, W Teeyasoontranon, N Ngo-Giang-Huong, ... Clinical Infectious Diseases 69 (1), 144-146, 2019 | 31 | 2019 |
| Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child … N Salvadori, B Fan, W Teeyasoontranon, N Ngo-Giang-Huong, ... Clinical Infectious Diseases 69 (1), 144-146, 2019 | 31 | 2019 |
| HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom UK Collaborative Group on HIV Drug Resistance, DN Chilton, H Castro, ... Antiviral therapy 15 (7), 985-991, 2010 | 27 | 2010 |
| Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings TS Torres, LJ Harrison, AM La Rosa, JA Lavenberg, L Zheng, SA Safren, ... AIDS care 30 (8), 954-962, 2018 | 24 | 2018 |
